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Background: Resistance to 5-fluorouracil (5-FU) in patients with colorectal cancer prevents effective treatment and
leads to unnecessary and burdensome chemotherapy. Therefore, prediction of 5-FU resistance is imperative.
Methods: To identify the proteins linked to 5-FU resistance, two-dimensional gel electrophoresis-based proteomics
was performed using the human colon cancer cell line SNU-C4R with induced 5-FU resistance. Proteins showing
altered expression in SNU-C4R were identified by matrix-associated laser desorption/ionization–time-of-flight
analysis, and their roles in susceptibility to 5-FU or radiation were evaluated in various cell lines by transfection
of specific siRNA or creation of overexpression constructs. Changes in cellular signaling and expression of mitochondrial
apoptotic factors were investigated by Western Blot analysis. A mitochondrial membrane potential probe (JC-1 dye) and a
flow cytometry system were employed to determine the mitochondrial membrane potential. Finally, protein levels
were determined by Western Blot analysis in tissues from 122 patients with rectal cancer to clarify whether each
identified protein is a useful predictor of a chemoradiation response.
Results: We identified mitochondrial phosphoenolpyruvate carboxykinase (mPEPCK) as a candidate predictor of
5-FU resistance. PEPCK was downregulated in SNU-C4R compared with its parent cell line SNU-C4. Overexpression
of mPEPCK did not significantly alter the susceptibility to either 5-FU or radiation. Suppression of mPEPCK led to a
decrease in both the cellular level of phosphoenolpyruvate and the susceptibility to 5-FU and radiation. Furthermore,
the cellular levels of phosphoenolpyruvate (an end product of PEPCK and a substrate of pyruvate kinase), phosphorylated
AKT, and phosphorylated 4EBP1 were decreased significantly secondary to the mPEPCK suppression in SNU-C4. However,
mPEPCK siRNA transfection induced changes in neither the mitochondrial membrane potential nor the expression levels
of mitochondrial apoptotic factors such as Bax, Bcl-2, and Bad. Downregulation of total PEPCK was observed in tissues
from patients with rectal cancer who displayed poor responses to preoperative 5-FU-based radiation therapy.
Conclusion: Our overall results demonstrate that mPEPCK is a useful predictor of a response to chemoradiotherapy in
patients with rectal cancer.
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Table 1 Characteristics of patients with rectal cancer









Tumor distance from anal verge (cm),
median (range)
6 (0-9)
Pretreatment CEA (ng/mL), median (range) 4 (0.5-206)
Histologic grade
Well differentiated 29 (23.8)
Moderately differentiated 91 (74.6)
Poorly differentiated 1 (0.8)
Unknown 1 (0.8)

















ECOG PS: indicates Eastern Collaborative Oncology Group Performance Status.
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The use of 5-fluorouracil (5-FU) as a chemotherapeutic
agent for colorectal cancer (CRC) is pervasive in the field
of medicine because of its ability to act as an S-phase-
specific antimetabolite and to suppress cell proliferation
[1,2]. In chemoradiotherapy (CRT), radiation is often per-
formed in conjunction with 5-FU [3]. However, resistance
to radiation has been reported in some patients with CRC,
and their poor response to either 5-FU or radiation treat-
ment makes preoperative CRT ineffective and burden-
some. Activated NF-κB along with other NF-κB–regulated
gene products, such as Bcl-xL, cyclin D1, matrix metallo-
proteinase 9, vascular endothelial growth factor, or
COX-2, might contribute to radiation resistance by
promoting prosurvival signaling [4]. Ashele et al. found
that 5-FU resistance may be caused by impaired polyglu-
tamylation of the thymidylate synthase cofactor CH2FH4
and decreased incorporation of 5-FU into RNA [5].
Phosphoenolpyruvate carboxykinase (PEPCK) is known
to exist in both the cytosol and mitochondria in the
mouse, human, and chicken. This enzyme catalyzes the
reversible decarboxylation of oxaloacetic acid with the
concomitant transfer of the gamma-phosphate of GTP to
form phosphoenolpyruvate (PEP) and GDP [6,7]. Cyto-
solic PEPCK has been investigated extensively and is
considered to be a key enzyme in gluconeogenesis and
glyceroneogenesis [8,9]. In contrast, the mitochondrial
isoform of PEPCK (mPEPCK) has a metabolic role that
is complementary to but distinct from that of cytosolic
PEPCK in the regulation of gluconeogenesis [9].
In this study, we found that mPEPCK is downregu-
lated in the human colon cancer cell line SNU-C4R with
induced 5-FU resistance. We herein present the results
of this study and discuss how the total amount of PEPCK
may affect the CRT response.
Methods
Human colon cancer cell lines and establishment of
5-FU–resistant cell lines
The human colon cancer cell lines SNU-C4, SNU-C5,
SNU-81, SNU-407, DLD-1, SW620, LoVo, HCT-116,
NCI-H747, NCI-H508, and CaCo2 were obtained from
the Korean Cell Line Bank (Seoul, Korea). The cell line
SNU-C4R, which is resistant to the anticancer agent
5-FU (Choongwae Pharma Corporation, Gyeonggi, Korea),
was derived from SNU-C4 as described previously [10].
Tissue from patients with CRC
All patients included in this study provided written in-
formed consent to participate. The study protocol was
approved by the Institutional Review Board of the Na-
tional Cancer Center. In total, 122 patients with locally
advanced mid/low rectal cancer who had undergone
preoperative CRT and radical proctectomy at the NationalCancer Center of Korea were enrolled in this study
(Table 1). All patients underwent a staging workup before
preoperative CRT. Tumor tissues had been obtained by
colonoscopic biopsy prior to treatment. As described in
previous studies, radiotherapy was delivered to the
whole pelvis at a dose of 45 Gy in 25 fractions followed
by a 5.4-Gy boost in 3 fractions within 6 weeks (n = 103)
or a dose of 25 Gy over 5 consecutive days using helical
tomotherapy (TomoTherapy, Inc., Madison, WI) (n = 19)
[11,12]. Concurrent chemotherapy was administered to
all patients in the form of a fluoropyrimidine-based
chemotherapeutic regimen: 5-fluorouracil and leucovorin
Park et al. BMC Cancer 2014, 14:160 Page 3 of 12
http://www.biomedcentral.com/1471-2407/14/160(n = 84; one or two cycles of 5-FU [400 mg/m2] and leucov-
orin [20 mg/m2] during RT), capecitabine (n = 6; oral ad-
ministration of capecitabine [825 mg/m2] twice daily during
RT without weekend breaks), or uracil-tegafur (n = 32; oral
administration of uracil-tegafur [400 mg/m2/day] and leu-
covorin [90 mg/day] 5 days per week during radiation). All
patients underwent total mesorectal excision 4 to 8 weeks
after the completion of preoperative CRT. The pathological
tumor stage was determined according to the 6th TNM
classification system recommended by the American Joint
Committee on Cancer [13]. The CRT response was evalu-
ated using the tumor regression grade system proposed by
Dworak et al. [14]. The tumor regression grades were de-
fined as follows: grade 0, no regression; grade 1, dominant
tumor mass with obvious fibrosis and/or vasculopathy (min-
imal regression); grade 2, dominant fibrotic changes with
obvious tumor cells or groups of cells (moderate regression);
grade 3, fibrotic tissue with or without mucous substance
containing very few tumor cells and that are difficult to de-
tect microscopically (near-complete regression); and grade
4, fibrotic mass or acellular mucin pools only, without de-
tectable tumor cells (complete regression). Tumors with
grade 3 or 4 regression comprised the “good response”
group. Other tumors comprised the “poor response” group.
MTT assay
A colorimetric assay using the tetrazolium salt MTT
(3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium brom-
ide) was used to assess suppression of cell survival by 5-FU
(Dong-A Pharmaceutical Co., Ltd., Seoul, Korea) and irradi-
ation. Cells grown in a 96-well plate were incubated with
5-FU and/or irradiated in a self-contained X-ray sys-
tem (X-RAD 320; Precision X-Ray, Inc., North Branford,
CT, USA) at 290 kV and 10 mA. The dose rate was
8 Gy/min. Single-cell suspensions were prepared, and
the cell density was measured. MTT assays were per-
formed as described previously [10]. All experiments
were performed three times, and the mean and standard
deviation of the half-maximal inhibitory concentration
(IC50, μg/ml) were calculated.
Two-dimensional gel electrophoresis-based comparative
proteomics
Two-dimensional gel electrophoresis (2-DE) analysis was
performed as described previously [10]. A 0.15-mg pro-
tein sample was applied to 13-cm immobilized nonlinear
gradient strips (pH 3–10), focused at 8000 V within 3 h,
and separated in 10% polyacrylamide gels (Serva, Heidelberg,
Germany; Bio-Rad, Hercules, CA). The 2-DE gels were
stained with Colloidal Coomassie Blue (Invitrogen,
Carlsbad, CA) for 24 h and then destained with deionized
water. Proteins showing abnormal expression were sub-
jected to matrix-associated laser desorption/ionization–
mass spectroscopy (MALDI-MS) analysis for identification.MALDI-MS analysis of 2-DE protein spots was performed
as previously described [10]. Mass spectra were first cali-
brated in the closed external mode using the 4700 Proteo-
mics Analyzer Calibration Mixture (AB SCIEX, Foster
City, CA) and analyzed with GPS Explorer software,
version 3.5 (AB SCIEX). The acquired MS/MS spectra
were searched against the Swiss-Prot and NCBI data-
bases by an in-house version of MASCOT.
Whole-protein extraction and subcellular fractionation
Cells or tissues were homogenized in four volumes of cell
lysis buffer (Pro-Prep; iNtRON Biotechnology, Gyeonggi,
Republic of Korea) using a Sample Grinding Kit (GE
Healthcare, Piscataway, NJ). The total homogenate was in-
cubated on ice for 20 min and centrifuged at 600 × g for
5 min. The supernatant was used as a whole protein ex-
tract. The cytosolic fraction was obtained by centrifuga-
tion of the whole protein extract at 11,000 × g for 10 min.
For isolation of an enriched, functional mitochondrial
fraction from cells, the Mitochondria Isolation Kit (Cata-
log No. MITISO1; Sigma, Saint Louis, MO) was used as
recommended by the manufacturer. Briefly, cells were
suspended with 10 volumes of the extraction buffer
(20 mM MOPS, pH 7.5, containing 110 mM KCl, 1 mM
EGTA, and 0.25 mg/ml trypsin) and incubated on ice for
3 min. The cells were then centrifuged for a few sec-
onds. The supernatant was removed by aspiration, and
eight volumes of the extraction buffer were added. After
incubation on ice for 20 min, the albumin solution was
added to a final concentration of 10 mg/ml to quench
the proteolytic reaction. The solution was then centri-
fuged for a few seconds. The supernatant was removed
by aspiration, and the pellet was washed with 8 volumes
of the extraction buffer. This step was repeated. The pel-
let was then homogenized and centrifuged at 600 × g for
5 min. The supernatant liquid was transferred to a new
tube and centrifuged at 11,000 × g for 10 min. The pellet
was suspended in the storage buffer (10 mM HEPES,
pH 7.4, containing 250 mM sucrose, 1 mM ATP,
0.08 mM ADP, 5 mM sodium succinate, 2 mM K2HPO4,
and 1 mM DTT [~40 ml per 100 mg of tissue]) and used
as a mitochondrial fraction.
Western blot analysis
Western Blot analysis was performed as described previ-
ously [10]. Supernatants of cell homogenates containing
equivalent amounts of protein were subjected to SDS-
PAGE and transferred to polyvinylidene fluoride mem-
branes (Millipore, Bedford, MA). The membranes were
incubated for 2 h at room temperature with primary
anti-PEPCK antibody that attaches to both cytosolic
and mitochondrial PEPCK) (Catalog No. sc-32879;
Santa Cruz Biotechnology, Inc., Dallas, TX), VDAC
(Abcam, Cambridge, UK), actin (Capital Bioscience,
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(Abcam), AKT (Cell Signaling Technology, Inc., Danvers,
MA), 4EBP1 (Cell Signaling Technology, Inc.), mTOR
(Cell Signaling Technology, Inc.), p-AKT (Ser 473; Cell
Signaling Technology, Inc.), p-mTOR (Ser 2448; Cell
Signaling Technology, Inc.), or p-4EBP1 (Thr 70; Cell
Signaling Technology, Inc.). The membranes were washed,
incubated with diluted HRP-conjugated secondary antibody
(SouthernBiotech, Birmingham, AL), and exposed to film
(Blue XB-1; Kodak, Rochester, NY).
Measurement of PEP
The level of intracellular PEP was measured using a PEP
assay kit (BioVision Inc., Milpitas, CA) as recommended
by the manufacturer.
siRNA transfection
Transfection of mPEPCK siRNA (Santa Cruz Biotech-
nology, Santa Cruz, CA) and negative control siRNA
(Qiagen, Chatsworth, CA) was performed with the HiPer-
Fect transfection reagent (Qiagen, Hilden, Germany) ac-
cording to the manufacturer’s protocol.
mPEPCK expression construct
To generate pEGFPc1-mPEPCK, a human fetal liver
cDNA library (Clontech, Mountain View, CA) was PCR-
amplified with the following oligomers specific to humanFigure 1 Downregulated mitochondrial phosphoenolpyruvate carbox
with induced 5-FU resistance. (a) Selection of downregulated protein sp
protein was identified as being downregulated in SNU-C4R. (b) Identificatio
identified as mPEPCK. (c) Western Blot analysis for confirmation of downreg
isoforms) and mPEPCK expression was significantly lower in SNU-C4R than inmPEPCK (Macrogen, Seoul, Korea): sense, 5′-GGAATT
CCATGGCCGCATTGTACCGCC-3′ and antisense, 5′-
CGGGATCCTCAGGTCACATTTTGTGCACACGTC-3′.
The amplified DNA was digested with EcoRI-BamHI and
then inserted into pEGFPc1 (Clontech). The construct
was verified by DNA sequencing (Cosmo Genetech, Seoul,
Korea).Detection of mitochondrial membrane potential
Cells were treated with 5-FU and radiation as de-
scribed above, then dislodged by trypsin. After centri-
fugation, the pelleted cells were washed with PBS and
suspended in 5 μg/ml of 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolylcarbocyanine iodide (JC-1 dye;
Molecular Probes, Eugene, OR) for 15 min at 37°C in
an incubation chamber. The cells were washed again with
PBS and then resuspended in PBS. The stained cells were
analyzed for their relative apoptosis content using a flow
cytometry system (FACSCalibur; BD Biosciences, Franklin
Lakes, NJ).Statistical analyses
Between-group differences were calculated using Student’s
t-test, and within-group correlations were calculated using
Spearman’s rank-coefficient. Statistical significance was set
at P < 0.05.ykinase (mPEPCK) in the human colon cancer cell line SNU-C4R
ot on 2-DE gel images. By comparing the 2-DE gel images, a ~100-kDa
n of mPEPCK by MALDI-MS analysis. The selected protein spot was
ulation of mPEPCK in SNU-C4R. Total PEPCK (cytosolic and mitochondrial
its parent cell line SNU-C4.
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Downregulated mPEPCK in human colon cancer cell line
SNU-C4R with induced 5-FU resistance and its correlation
with 5-FU response
We performed 2-DE to investigate dysregulated protein
expression in the human colon cancer cell line SNU-
C4R with induced 5-FU resistance. In 2-DE gel image
analysis, a ~100-kDa protein was identified as being
downregulated in SNU-C4R (Figure 1a). This protein spot
was identified as mPEPCK through MALDI-MS analysis
and confirmed by Western Blot (Figure 1b and c).
Differential PEPCK expression levels in the whole ho-
mogenates and mitochondrial fractions from 11 humanFigure 2 Quantification of PEPCK expression levels in 11 human colo
levels of PEPCK in whole homogenates and mitochondrial fractions of di
(b) Differential responses of cell lines to 5-FU. The 5-FU IC50 was determ
assay. (c) No correlation was observed between mPEPCK expression and
cell lines were plotted against their PEPCK expression levels in whole homoge
to actin and VDAC, respectively.colon cancer cell lines were detected by Western Blot and
normalized to actin and VDAC, respectively (Figure 2a).
As expected, the 5-FU IC50 (the concentration of 5-FU
that results in a 50% decrease in cell survival compared
with control) varied among CRC cell lines (Figure 2b).
However, the PEPCK expression levels in neither the
mitochondrial fractions nor the whole homogenates
showed a correlation with 5-FU IC50 (Figure 2c).
Decreased cellular level of PEP and reduced susceptibility to
5-FU/radiation induced by mPEPCK suppression in SNU-C4
mPEPCK siRNA transfection was performed using SNU-
C4 to investigate the role of mPEPCK in 5-FU resistance.n cancer lines with different responses to 5-FU. (a) The expression
fferent cell lines were normalized with actin and VDAC, respectively.
ined in 11 colon cancer cell lines 96 h after 5-FU treatment by MTT
the responses of cell lines to 5-FU. The 5-FU IC50 values of the various
nates (upper panel) and mitochondrial fractions (lower panel) normalized
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was detected in the mPEPCK-suppressed cells than in the
nonsilenced (NS) control (Figure 3a). mPEPCK sup-
pression itself reduced the proliferation rate of SNU-C4
without any 5-FU or radiation treatment (Figure 3b). Fur-
thermore, the cellular level of PEP (an end product of
PEPCK and substrate of pyruvate kinase) was also signifi-
cantly decreased by the mPEPCK suppression in SNU-C4
(Figure 3c). The survival rates of the mPEPCK-suppressed
SNU-4 cells after 1 μg/ml 5-FU treatment or 8-Gy radiationFigure 3 Effect of mPEPCK downregulation on 5-FU response in SNU-
with mPEPCK siRNA. The PEPCK expression levels decreased over time in th
showed no apparent changes in the PEPCK expression levels. (b) Decrease
radiation treatment, artificial suppression of mPEPCK decreased the rat
suppression. (d) Increased 5-FU and radiation resistance was observed
the mPEPCK siRNA-transfected SNU-C4 cells exhibited higher survival r
and radiation.were higher than those of the control, but the difference did
not reach statistical significance (P = 0.082 and 0.069,
respectively) (Figure 3d). Suppression of mPEPCK sig-
nificantly increased survival of SNU-4 cells after combined
treatment comprising 5-FU and radiation (P = 0.0005)
(Figure 3d).
The effects of mPEPCK overexpression using pEGFPc1-
mPEPCK vector were also investigated. Overexpressed
mPEPCK was localized in the cytoplasm rather than in
the mitochondria (data not shown). Overexpression ofC4 cells. (a) Suppressed mPEPCK expression in SNU-C4 cells transfected
e mPEPCK siRNA-transfected cells, while the nonsilenced (NS) control
d cell proliferation rate after mPEPCK suppression. With no 5-FU or
e of cell proliferation. (c) Reduced cellular PEP level after mPEPCK
after mPEPCK suppression in SNU-C4 cells. MTT assay showed that
ates than the control after combination treatment comprising 5-FU
Figure 4 Effect of mPEPCK overexpression on 5-FU response in SNU-C4 cells. Overexpression of mPEPCK in (a) SNU-C4 and (c) LoVo transfected
with pEGFPc1-mPEPCK. Upregulated mPEPCK was monitored over 24-, 48-, 72-, and 96-h time periods by Western Blot, while the pEGFPc1-transfected
control showed no changes in PEPCK expression levels. No effect of overexpression of mPEPCK was observed in (b) SNU-C4 or (d) LoVo on the
susceptibility to 5-FU, irradiation, or combination treatment comprising 5-FU and irradiation. Overexpression of mPEPCK slightly increased
the susceptibility to 5-FU in both SNU-C4 and LoVo cells, but the difference was not statistically significant.
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susceptibility to 5-FU (P = 0.067), but not to radiation
or combined treatment (P = 0.21 and 0.39, respectively)(Figure 4). The response of LoVo to 5-FU/radiation
after mPEPCK overexpression showed a pattern similar
to that of SNU-C4 (Figure 4c and d).
Figure 5 (See legend on next page.)
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Figure 5 Cellular changes in mPEPCK-suppressed SNU-C4 cells. (a) No change in the mitochondrial membrane potential or apoptotic cell
death was observed in SNU-C4 transfected with mPEPCK siRNA. Flow cytometry was performed using JC-1 to determine the mitochondrial
membrane potential and apoptotic cell death rate. (b) No changes in apoptosis-related mitochondrial proteins were observed in the non-transfected,
NS, or mPEPCK siRNA-transfected SNU-C4 cells. Whole cellular homogenate, mitochondrial, and cytosolic fractions were used for Western Blot analysis.
Expression of Bax, Bcl-2, and Bad was not affected by mPEPCK suppression. (c) Altered phosphorylation level of main signaling molecules
after mPEPCK suppression in SNU-C4 cells. Phosphorylation levels of AKT and 4EBP1 were significantly decreased in SNU-C4 cells after
mPEPCK siRNA transfection.
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membrane potential and signal-transducing molecules
To determine whether the decreased cell survival after
mPEPCK suppression was caused by alteration of the
mitochondrial membrane potential, JC-1 dye and the
FACSCalibur flow cytometry system were employed to
determine the mitochondrial membrane potential. How-
ever, neither 1 μg/ml 5-FU treatment nor 8-Gy radiation
resulted in a significant difference between the mPEPCK
siRNA-transfected cells and the control in terms of the
mitochondrial membrane potential or level of apoptosis
following the change in the mitochondrial potential
(Figure 5a). Further Western Blot analysis revealed
that the expression levels of mitochondrial apoptotic
factors such as Bax, Bcl-2, and Bad also remained un-
changed in the mPEPCK-suppressed cells (Figure 5b).
Examination of the phosphorylation level of signal-
transducing molecules after mPEPCK siRNA transfection
revealed lower levels of phosphorylated AKT (p-AKT) and
phosphorylated 4EBP1 (p-4EBP1) in mPEPCK siRNA-
transfected cells than in the NS control or normal, non-
transfected SNU-C4 line (Figure 5c).
Poor response to CRT in patients with rectal cancer is
associated with low PEPCK expression
The expression levels of total PEPCK (cytoplasmic plus
mitochondrial PEPCK) in 122 patients with rectal cancer
were measured by Western Blot, and the optical dens-
ities of the spots were measured from scanned images
(Figure 6a; Additional file 1: Table S1). The PEPCK ex-
pression levels of SNU-C4 and HCT-116 were used as
controls. The levels of PEPCK expression were signifi-
cantly lower in tumors with a poor response (tumor re-
gression grade of 1 or 2) than in those with a good
response (tumor regression grade of 3 or 4) (P = 0.004)
(Figure 6b).
Discussion
In this study, we investigated the possible role of mPEPCK
as a predictor of 5-FU and radiation susceptibility in pa-
tients with CRC. Using different CRC cell lines and tumor
tissues of patients with CRC who were treated with 5-FU-
based CRT, we showed that mPEPCK was downregulated
in 5-FU–resistant cells and tumor tissues of patients who
were resistant to 5-FU–based CRT. Several mechanismsof reduced PEPCK expression have been proposed. Anti-
oxidants can suppress PEPCK expression through the
transcription factor activator protein 1, or PEPCK can be
degraded by proteasome pathways in response to high
glucose levels [15,16]. Although the cause of PEPCK
downregulation in nonresponders to 5-FU–based CRT
has not yet been elucidated, low PEPCK expression seems
to be related to a poor response.
Downregulation of mPEPCK in the human colon can-
cer cell line SNU-C4R with induced 5-FU resistance was
confirmed by 2-DE and MALDI-MS (Figure 1a and b).
mPEPCK expression and responses to 5-FU differed
among the 11 human colon cancer cell lines (Figure 2).
However, there was no significant correlation between
mPEPCK expression and 5-FU susceptibility in any of
these 11 colon cancer cell lines (Figure 2c). This finding
suggests that downregulation of mPEPCK may be linked
to induced 5-FU resistance, not intrinsic 5-FU suscepti-
bility, in colon cancer cells. mPEPCK was suppressed
using mPEPCK siRNA to clarify the role of mPEPCK in
the cellular response to 5-FU, and successful suppression
was confirmed by the observation of decreasing PEPCK ex-
pression levels over time after siRNA transfection (Figure 3a).
Compared with the NS control, the mPEPCK-suppressed
SNU-C4 cells demonstrated slower proliferation (Figure 3b),
but a higher survival rate, after combined treatment com-
prising 5-FU and radiation (P = 0.0005) (Figure 3d). These
findings suggest the involvement of mPEPCK in response to
both 5-FU and radiation. Slow growth may be caused by
downregulated energy metabolism. Because PEP is the final
product of PEPCK as well as the substrate of pyruvate kin-
ase, which is an enzyme involved in a rate-limiting step of
glycolysis, a low cellular level of PEP followed by mPEPCK
suppression may lead to slow proliferation of colon cancer
cells (Figure 3b and c). Our previous reports showed that
low energy metabolism and slow proliferation can decrease
the susceptibility of cancer cells to anticancer drugs [17,18].
Although upregulated expression of mPEPCK showed the
potential to slightly increase the 5-FU susceptibility in
both the SNU-C4 and LoVo cell lines, the effects were
not statistically significant (Figure 4). Because overex-
pressed mPEPCK was not found in the mitochondrial
fraction (data not shown), further investigations are
necessary to validate the effect of subcellular localization
of this enzyme on CRT susceptibility.
Figure 6 (See legend on next page.)
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Figure 6 PEPCK expression levels in patients with rectal cancer. (a) Western Blot analysis was performed to determine the PEPCK expression
levels in 122 patients with rectal cancer. The patients were divided into poor and good response groups according to their response to
chemoradiotherapy (see Methods). The PEPCK expression levels in SNU-C4 and HCT-116 were used as controls. (b) PEPCK expression levels were
linked to the chemoradiotherapy response. The PEPCK expression levels were normalized to the actin expression levels.
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largely unknown, recent reports suggest that mPEPCK
plays various roles in gluconeogenesis and anaplerotic reac-
tions. For example, mPEPCK plays a role in mitochondrial
GTP synthesis with insulin release through anaplerotic PEP
cycling [19] and cooperates with cytosolic PEPCK to adjust
gluconeogenic/TCA flux in response to changes in sub-
strate or energy availability [8]. At present, we cannot
explain the molecular mechanism linking mPEPCK ex-
pression and susceptibility of CRC cells to 5-FU or ra-
diation. However, expression of both cytosolic PEPCK
and mPEPCK may indicate changes in gluconeogenic flux
because PEPCK expression can be exquisitely coordinated
in parallel with glucose requirements [20]. Our previous
reports have shown that the slow energy metabolic
process caused by downregulation of key enzymes, such
as mitochondrial ATP synthase and pyruvate kinase M2,
lead to differential responses of cancer cells to anticancer
drugs [17,18]. Thus, mPEPCK downregulation could also
lead to slow energy metabolism in CRC cells, and it may
subsequently reduce the susceptibility of CRC cells to
5-FU or radiation.
5-FU is known to act as an S-phase-specific antimetabolite
that suppresses cell proliferation [1,2]. When it enters cells,
fluorouracil is converted to 5-fluoro-2′-deoxyuridylate,
which can competitively inhibit thymidylate synthase and
block the formation of deoxythymidylate, which is required
for DNA synthesis [2]. However, the flow cytometry results
showed that after 1 μg/ml 5-FU treatment or 8-Gy radiation,
the mPEPCK siRNA-transfected cells did not exhibit a
significantly different mitochondrial membrane poten-
tial or level of apoptosis compared with the NS control
(Figure 5a). This finding suggests that downregulation
of mPEPCK may affect the energy metabolism of can-
cer cells, leading to slow proliferation, but that mPEPCK
itself cannot augment apoptotic cell death by either 5-FU
or radiation treatment. Bad forms a heterodimer with
Bcl-2, which is known to induce cells to persist in a G-0
state and to promote cell survival by inhibiting the caspase
cascade activation induced by cytochrome c [19,20].
Therefore, in effect, this heterodimer formation coun-
ters the antiapoptotic effects of Bcl-2, allowing Bax/
Bak-triggered apoptosis [21]. Previous studies have
also found that Bax interacts with the permeability
transition pore to lower the mitochondrial membrane
potential and release cytochrome c, inducing apoptosis
[22]. We therefore examined the expression levels of
mitochondrial molecules such as Bax, Bcl-2, and Badin our study. However, in line with the flow cytometry
results, the mitochondrial expression levels of Bax, Bcl-2,
and Bad were not altered in the mPEPCK siRNA-
transfected cells (Figure 5b). To identify a link between
mPEPCK and cellular events, we finally investigated the
expression of the main cellular signaling pathway mole-
cules, such as AKT, 4EBP1, and mTOR, which are in-
volved in important pathways downstream of Ras
(Figure 5c). Lower amounts of p-4EBP1 and p-AKT
were detected in the mPEPCK-silenced cells than in
the nontransfected SNU-C4 or the NS control (Figure 5c).
4EBP1 plays an important role in the control of protein
synthesis, survival, and cell growth [23,24]. When phos-
phorylated, 4EBP1 has a reduced binding affinity for
EIF4E, which leads to the release of EIF4E and the initi-
ation of cap-dependent translation [21]. p-AKT promotes
growth factor-mediated cell growth and phosphorylates
Bad, hindering apoptosis [22]. Decreased expression levels
of p-AKT and p-4EBP1 in the mPEPCK-silenced cells im-
plies that mPEPCK downregulation may not only decrease
normal cellular metabolism (Figure 3c), but may be linked
to broad cellular events such as abnormal protein synthe-
sis and slow cell proliferation and growth.
To clarify whether our in vitro results can be applied
clinically, PEPCK expression levels were determined in
tissues from patients with rectal cancer who had under-
gone preoperative CRT. Because of the small amount of
tissues available, the mitochondrial fraction could not be
isolated from the tissues. However, lower expression
levels of total PEPCK (cytosolic and mitochondrial iso-
forms) in patients’ tumors seemed to be correlated with
poorer responses to CRT (Figure 5b). Predicting the
tumor response to preoperative CRT can help to tailor
treatment plans for locally advanced rectal cancer.
PEPCK can be used as a candidate biomarker for pre-
dicting the rectal tumor response to CRT. Further stud-
ies using standardized measurements and validation will
be needed to fully elucidate the potential clinical applica-
tion of PEPCK as a predictor.
Conclusions
In conclusion, further studies are needed to elucidate the
critical role of PEPCK in 5-FU–based CRT responses.
Additionally, a larger sample size is required to confirm
the use of PEPCK as a prognostic factor for CRC. How-
ever, the present results demonstrate that the slow en-
ergy metabolic process caused by downregulation of
PEPCK may lead to different responses of CRC cells
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